baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out BAYN/ DE000SU0X1Y5 /

2024-07-29 5:39:35 PM	Chg.0.00	Bid10:00:34 PM	Ask10:00:34 PM	Underlying	Strike price	Expiration date	Option type
14.07EUR	0.00%	- Bid Size: -	- Ask Size: -	BAYER AG NA O.N.	13.5285 EUR	2078-12-31	Call

GlobeNewswire 06-25 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial

GlobeNewswire 05-30 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

GlobeNewswire 05-30 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...

GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 05-28 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement

TeleTrader 05-14 Bayer's sales in Q1 at €13.7 billion, down 4.3%

GlobeNewswire 05-02 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...

GlobeNewswire 04-18 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...

GlobeNewswire 04-16 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...

GlobeNewswire 04-11 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...

GlobeNewswire 04-09 AskBio Names Mansuo Shannon Chief Scientific Officer

GlobeNewswire 03-25 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...

GlobeNewswire 03-14 Bayer and Aignostics to collaborate on next generation precision oncology

GlobeNewswire 03-06 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...

TeleTrader 03-05 Bayer's Q4 sales at €11.9 billion

GlobeNewswire 03-04 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

TeleTrader 03-04 Earnings preview: Bayer, Broadcom among those in calendar

GlobeNewswire 02-15 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust

GlobeNewswire 02-13 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...

GlobeNewswire 02-13 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

TeleTrader 01-29 Bayer down over 5% after latest $2.25B Roundup ruling

TeleTrader 01-17 Bayer to cut jobs amid 'difficult situation'

GlobeNewswire 01-05 AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

GlobeNewswire 01-04 AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...

GlobeNewswire 2023-12-14 Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Su...

Soc. Generale Knock-Out BAYN/ DE000SU0X1Y5 /

If you wish to receive reply to your feedback, please provide your email address.